Aurobindo Pharma Limited Stock Price Today (NSE: AUROPHARMA)
Fundamental Score
Aurobindo Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aurobindo Pharma Limited share price today is ₹1645.00, down 2.20% on NSE/BSE as of 8 October 2026. Aurobindo Pharma Limited (AUROPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹94.65K (Cr). The 52-week high for AUROPHARMA share price is ₹1740.00 and the 52-week low is ₹1066.80. At a P/E ratio of 25.70x, AUROPHARMA is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.94% and a debt-to-equity ratio of 0.20.
Aurobindo Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Aurobindo Pharma Limited share price chart: 2.67% return over the past month. 52-week high ₹1740.00, 52-week low ₹1066.80.
Aurobindo Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1679.10 | ₹1681.90 | ₹1641.00 | ₹1645.00 | 4.39L (Cr) | |
| ₹1696.20 | ₹1698.90 | ₹1670.50 | ₹1682.00 | 4.38L (Cr) | |
| ₹1676.00 | ₹1694.70 | ₹1670.90 | ₹1692.80 | 10.10L (Cr) | |
| ₹1693.70 | ₹1696.00 | ₹1663.10 | ₹1674.90 | 9.59L (Cr) | |
| ₹1677.90 | ₹1700.70 | ₹1654.20 | ₹1676.80 | 10.74L (Cr) | |
| ₹1696.00 | ₹1707.20 | ₹1649.30 | ₹1672.00 | 11.39L (Cr) | |
| ₹1697.00 | ₹1713.70 | ₹1690.70 | ₹1697.70 | 11.59L (Cr) | |
| ₹1712.00 | ₹1713.40 | ₹1686.80 | ₹1697.50 | 6.58L (Cr) | |
| ₹1716.00 | ₹1727.90 | ₹1699.50 | ₹1712.00 | 6.25L (Cr) | |
| ₹1719.70 | ₹1740.00 | ₹1710.00 | ₹1716.00 | 8.20L (Cr) |
Aurobindo Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1677.90 | ₹1700.70 | ₹1641.00 | ₹1645.00 | -1.96% | |
| ₹1700.00 | ₹1740.00 | ₹1622.60 | ₹1672.00 | -1.65% | |
| ₹1586.90 | ₹1717.00 | ₹1536.80 | ₹1717.00 | +8.20% | |
| ₹1578.70 | ₹1636.80 | ₹1512.00 | ₹1580.20 | +0.10% | |
| ₹1426.40 | ₹1588.90 | ₹1391.00 | ₹1578.70 | +10.68% | |
| ₹1398.00 | ₹1550.00 | ₹1367.00 | ₹1426.40 | +2.03% | |
| ₹1332.20 | ₹1459.50 | ₹1266.10 | ₹1389.50 | +4.30% | |
| ₹1186.20 | ₹1330.00 | ₹1179.80 | ₹1304.40 | +9.96% | |
| ₹1172.10 | ₹1250.90 | ₹1106.00 | ₹1220.40 | +4.12% | |
| ₹1190.00 | ₹1270.80 | ₹1116.20 | ₹1207.70 | +1.49% | |
| ₹1229.00 | ₹1240.70 | ₹1160.50 | ₹1183.00 | -3.74% | |
| ₹1142.90 | ₹1249.90 | ₹1120.00 | ₹1226.70 | +7.33% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aurobindo Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aurobindo Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROPHARMA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Operating Margins (19.65%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 25.70 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (25.20%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.30%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.20)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.81)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹5096.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 41.06%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
4 factors identified
Below-Average Return on Equity (9.94%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (-7.90% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-8.07% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
High Share Pledging Risk (23.65%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Aurobindo Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aurobindo Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aurobindo Pharma LimitedAurobindo Pharm...Selected✓ AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹94653.30₹94653.30 | 25.70Average 25.7 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Glenmark Pharmaceuticals LimitedGlenmark Pharma... GLENMARK • 532296 | 70.7/100 | ₹2408.40₹2408 | ₹67965.05₹67965.05 | 37.80Average 37.8 Average | 0.00%Poor 0.00% Poor | 18.58%Good 18.58% Good | 0.00Excellent 0.0 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Aurobindo Pharma Limited PE Ratio History
Historical price-to-earnings ratio for AUROPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹59.81 | ₹1183.00 | 19.8x |
| FY 2024 | ₹54.16 | ₹1334.50 | 24.6x |
| FY 2023 | ₹32.90 | ₹1084.00 | 32.9x |
| FY 2022 | ₹45.19 | ₹438.30 | 9.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aurobindo Pharma Limited Dividend History
Annual cash dividends paid by AUROPHARMA — dividend yield 0.26%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.04 Cr |
| FY 2024 | ₹263.64 Cr |
| FY 2023 | ₹439.53 Cr |
| FY 2022 | ₹263.70 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aurobindo Pharma Limited Quarterly Performance
Latest quarterly metrics for AUROPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.30%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
25.20%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.32%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-8.07%
Compounded annual net profit growth over 5 years
Aurobindo Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AUROPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aurobindo Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Aurobindo Pharma Limited (AUROPHARMA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Aurobindo Pharma Limited
About AUROPHARMA (Aurobindo Pharma Limited)
Aurobindo Pharma Ltd is a global pharmaceutical powerhouse, deeply rooted in the development and manufacturing of a diverse range of healthcare solutions. With a commitment to inno...vation and quality, the company focuses on delivering accessible medicines to patients worldwide. Their broad portfolio encompasses both finished drug formulations and active pharmaceutical ingredients, catering to a variety of therapeutic needs. From cutting-edge manufacturing facilities to a robust research and development infrastructure, Aurobindo Pharma strives to meet the ever-evolving demands of the global healthcare landscape. They operate with a global vision, aiming to expand their reach and impact on patient well-being through strategic partnerships and a dedication to excellence. Aurobindo Pharma specializes in crafting complex generic medications and crucial APIs, ensuring a steady supply of high-quality pharmaceutical products. The company's manufacturing prowess spans various dosage forms, including tablets, capsules, injectables, and inhalers, demonstrating their versatility and commitment to providing comprehensive treatment options. They possess a keen understanding of intricate chemical processes and advanced drug delivery systems. Their API business forms a cornerstone, supplying essential ingredients for numerous medications globally, further solidifying their position within the pharmaceutical ecosystem. This commitment extends to continuous improvement in manufacturing efficiency, sustainability, and adherence to the most stringent regulatory standards. Aurobindo Pharma’s therapeutic focus covers a wide spectrum of medical needs, reflecting their dedication to addressing diverse health challenges. Their offerings include medications targeting cardiovascular ailments, neurological disorders, infectious diseases, and metabolic conditions, among others. By investing in research and development, they strive to create innovative and effective treatments that improve patient outcomes and quality of life. Their dedication to research extends to the development of biosimilars, offering affordable alternatives to complex biologic drugs. This multifaceted approach underscores Aurobindo Pharma's commitment to healthcare accessibility and their mission to serve as a reliable provider of essential medicines to communities around the globe.
Company Details
Key Leadership
AUROPHARMA Share Price: Frequently Asked Questions
What is the current share price of Aurobindo Pharma Limited?
Aurobindo Pharma Limited (AUROPHARMA) trades at ₹1645.00 on NSE and BSE. Market cap ₹94.65K (Cr). Educational data only.
What is the P/E ratio of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has a P/E of 25.70x vs industry average 34.89x.
What is the Bull Run score for Aurobindo Pharma Limited?
Aurobindo Pharma Limited has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Aurobindo Pharma Limited pay dividends?
Aurobindo Pharma Limited has a dividend yield of 0.26%. Past dividends don't guarantee future payments.
What is the ROE of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has ROE of 9.94%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has debt-to-equity of 0.20.
Is Aurobindo Pharma Limited a good investment?
Bull Run gives Aurobindo Pharma Limited a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.